| OCUGEN INC. DL-,001 |
| USA |
| Gesundheit |
| US67577C1053 / A2PSZH |
| 2H51 (Frankfurt) / OCGN (NASDAQ) |
| FRA:2H51, ETR:2H51, 2H51:GR, NASDAQ:OCGN |
| - |
| https://ocugen.com/ |
|
Ocugen Inc. is a clinical-stage biopharmaceutical company focused on developing gene and cell therapies for blindness diseases and other serious ocular conditions. Its current programs center on a modifier gene therapy platform designed to address in..
>Volltext.. |
| 401.05 Mio. EUR |
| 390.42 Mio. EUR |
| 3.95 Mio. EUR |
| -57.99 Mio. EUR |
| -70.62 Mio. EUR |
| -0.22 EUR |
| 75.95 Mio. EUR |
| 86.37 Mio. EUR |
| -52.54 Mio. EUR |
| 0.75 |
| -0.63% |
| -48.2% |
| - |
| - |
| - |
| - |
| OCUGEN |
| 01.09.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|